Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 222-241

  Aliev, Gjumrakch ^a   Li, Yi ^b   Palacios, Hector H ^c   Obrenovich, Mark E ^d  

^a University of Atlanta   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Biomarkers; Cerebrovascular diseases; Drug targets; Free radicals; Hypometabolism; Mitochondrial dna; Oxidation; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; DIAMINOBENZIDINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR KINASE 2; ISOENZYME; MITOCHONDRIAL DNA; NICOTINIC RECEPTOR; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; CELL DAMAGE; CELL DEATH; CEREBROVASCULAR ACCIDENT; DEFENSE MECHANISM; DISEASE COURSE; DRUG DEVELOPMENT; ENZYME REGULATION; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA; MICROVASCULATURE; MITOCHONDRION; OXIDATION; OXIDATIVE STRESS; PARENCHYMA; PERFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPERFUSION INJURY; RISK FACTOR; SMOKING; THERAPY;

EID: 80053467489     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797376942     Document Type: Article

References (195)

1. Skulachev M, Skulachev V. Use of Mitochondrially-addressed compounds for preventing and treating cardiovascular diseases. US20110053895 (2011).
2. Ames B, Hagen T. Dietary composition for enhancing metabolism and alleviating oxidative stress. US5916912 (1999).
3. Aliev G, Liu J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, et al. Neuronal mitochondrial amelioration by feeding acetyl-Lcarnitine and lipoic acid to aged rats. J Cell Mol Med 2009; 13: 320-333.
4. Thomas AJ, Morris CM, Ferrier IN, Kalaria RN. Distribution of amyloid beta 42 in relation to the cerebral microvasculature in an elderly cohort with Alzheimer's disease. Ann N Y Acad Sci 2000; 903: 83-88.
5. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154.
6. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 113-125.
7. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13 Suppl 3: S106-S114.
8. Aliev G, Burnstock G. Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol 1998; 13: 797-817.
9. Aliev G, Cirillo R, Salvatico E, Paro M, Prosdocimi M. Changes in vessel ultrastructure during ischemia and reperfusion of rabbit hindlimb: implications for therapeutic intervention. Microvasc Res 1993; 46: 65-76.
10. Smith MA, Petot GJ, Perry G. Commentary: Diet and Oxidative Stress: A Novel Synthesis of Epidemiological Data on Alzheimer's Disease. Alzheimer's Disease Review 1997; 2: 58-60.
11. Roses AD. On the metabolism of apolipoprotein E and the Alzheimer diseases. Exp Neurol 1995; 132: 149-156.
12. Aliev G. Is non-genetic Alzheimer's disease a vascular disorder with neurodegenerative consequences? J Alzheimers Dis 2002; 4: 513-516.
13. de la Torre JC. Alzheimer's disease: how does it start? J Alzheimers Dis 2002; 4: 497-512.
14. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 1996; 46: 1592-1596.
15. Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman BT, et al. Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. J Alzheimers Dis 1998; 1: 119-134.
16. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 1998; 252: 711-715.
17. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 2002; 12: 21-35.
18. Goldstein G. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions accosiated with oxidative stress. US20100137441 (2010).
19. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium- dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation 1995; 92: 1582-1589.
20. Grant DN. Dietary links to Alzheimer's disease. Alzheimer's Disease Review 1997; 2: 42-55.
21. Montine TJ, Montine KS, Swift LL. Central nervous system lipoproteins in Alzheimer's disease. Am J Pathol 1997; 151: 1571-1575.
22. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7: 321-331.
23. Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer's disease? Ann N Y Acad Sci 1997; 826: 128-146.
24. Sparks DL, Kuo YM, Roher A, Martin T, Lukas RJ. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann N Y Acad Sci 2000; 903: 335-344.
25. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000; 21: 331-342.
26. de la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev 2000; 34: 119-136.
27. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000; 21: 321-330.
28. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl 3: S115-S123.
29. Court JA, Lloyd S, Johnson M, Griffiths M, Birdsall NJ, Piggott MA, et al. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Brain Res Dev Brain Res 1997; 101: 93-105.
30. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20: 281-298.
31. Terzano S, Court JA, Fornasari D, Griffiths M, Spurden DP, Lloyd S, et al. Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. Brain Res Mol Brain Res 1998; 63: 72-78.
32. Hellstrom-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res 2000; 113: 159-168.
33. Perry EK, Court JA, Lloyd S, Johnson M, Griffiths MH, Spurden D, et al. Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe. Ann N Y Acad Sci 1996; 777: 388-392.
34. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999; 73: 1635-1640.
35. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: C719-C741.
36. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262: 689-695.
37. Perry G, Smith MA, McCann CE, Siedlak SL, Jones PK, Friedland RP. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Res 1998; 791: 63-66.
38. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, et al. Oxidative damage in Alzheimer's. Nature 1996; 382: 120-121.
39. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997; 17: 2653-2657.
40. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000; 1502: 139-144.
41. Smith MA, Sayre LM, Perry G. Is Alzheimer's a Disease of Oxidative Stress? Alzheimer's Disease Review 1996; 1: 63-67.
42. Smith MA, Vasak M, Knipp M, Castellani RJ, Perry G. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic Biol Med 1998; 25: 898-902.
43. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 1998; 51: 1562-1566.
44. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998; 23: 81-88.
45. Prelli F, Castano EM, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem Biophys Res Commun 1988; 151: 1150-1155.
46. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147.
47. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 1999; 9: 133-146.
48. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 1997; 31: 53-64.
49. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747-751.
50. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, et al. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann Neurol 1993; 34: 609-616.
51. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-767.
52. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 1999; 893: 362-364.
53. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999; 19: 1959-1964.
54. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 2000; 18: 417-421.
55. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-2097.
56. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, et al. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A 1994; 91: 5710-5714.
57. Cirillo R, Aliev G, Hornby EJ, Prosdocimi M. Endothelium as a therapeutical target in peripheral occlusive arterial diseases: consideration for pharmacological interventions. Pharmacol Res 1994; 29: 293-311.
58. Cirillo R, Salvatico E, Aliev G, Prosdocimi M. Effect of cloricromene during ischemia and reperfusion of rabbit hindlimb: evidence for an involvement of leukocytes in reperfusion-mediated tissue and vascular injury. J Cardiovasc Pharmacol 1992; 20: 969-975.
59. Granger DN, Benoit JN, Suzuki M, Grisham MB. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol 1989; 257: G683-8.
60. Sala A, Aliev GM, Rossoni G, Berti F, Buccellati C, Burnstock G, et al. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood 1996; 87: 1824-1832.
61. Salvatico E, Aliev GM, Novello D, Prosdocimi M. Functional depression of isolated perfused rat heart mediated by activated leu kocytes: protective effect of cloricromene. J Cardiovasc Pharmacol 1994; 24: 638-647.
62. Matz RL, Schott C, Stoclet JC, Andriantsitohaina R. Age-related endothelial dysfunction with respect to nitric oxide, endotheliumderived hyperpolarizing factor and cyclooxygenase products. Physiol Res 2000; 49: 11-18.
63. Stewart-Lee AL, Ferns GA, Anggard EE. Differences in onset of impaired endothelial responses and in effects of vitamin E in the hypercholesterolemic rabbit carotid and renal arteries. J Cardiovasc Pharmacol 1995; 25: 906-913.
64. Price JM, Sutton ET, Hellermann A, Thomas T. beta-Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol Res 1997; 19: 534-538.
65. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 1999; 2: 157-161.
66. Niwa K, Carlson GA, Iadecola C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab 2000; 20: 1659-1668.
67. Grammas P, Moore P, Weigel PH. Microvessels from Alzheimer's disease brains kill neurons in vitro. Am J Pathol 1999; 154: 337-342.
68. Stewart PA, Hayakawa K, Akers MA, Vinters HV. A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest 1992; 67: 734-742.
69. Aliev G, M.A. Smith, H. Vinters, A.B. Johnson, A. Nunomura, and G. Perry Mitochondria abnormalities mark vulnerable neurons in Alzheimer's disease. Journal of Neuropathology and Experimental Neurology 1999; 58: 511.
70. Vinters HV, Miller BL, Pardridge WM. Brain amyloid and Alzheimer disease. Ann Intern Med 1988; 109: 41-54.
71. Hock BJJaBTL. Transgenetic mouse models of Alzheimer's disease. TrendsGenet 2001 17: S7-S12.
72. Jakobovits A, Lamb BT, Peterson KR. Production of transgenic mice with yeast artificial chromosomes. Methods Mol Biol 2000; 136: 435-453.
73. Kulnane LS, Lamb BT. Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol Dis 2001; 8: 982-992.
74. Octave JN. The amyloid peptide precursor in Alzheimer's disease. Acta Neurol Belg 1995; 95: 197-209.
75. Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994; 10: 373-403.
76. Crawford JG. Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med Hypotheses 1998; 50: 25-36.
77. Lindahl B, Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 1997; 272: 26091-26094.
78. Kisilevsky R. Amyloid beta threads in the fabric of Alzheimer's disease. Nat Med 1998; 4: 772-773.
79. Iwamoto N, Nishiyama E, Ohwada J, Arai H. Distribution of amyloid deposits in the cerebral white matter of the Alzheimer's disease brain: relationship to blood vessels. Acta Neuropathol (Berl) 1997; 93: 334-340.
80. Kawai M, Kalaria RN, Harik SI, Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am J Pathol 1990; 137: 1435-4146.
81. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989; 135: 309-319.
82. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 1988; 58: 454-458.
83. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani O, Frangione B. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest 1990; 62: 761-767.
84. Acuna-Castroviejo D, Martin M, Macias M, Escames G, Leon J, Khaldy H, et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30: 65-74.
85. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 2002; 70: 357-360.
86. Fiskum G, Murphy AN, Beal MF. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J Cereb Blood Flow Metab 1999; 19: 351-369.
87. Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 1997; 174: 193-197.
88. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001; 21: 3017-3023.
89. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78: 547-581.
90. Beckman KB, Ames BN. Mitochondrial aging: open questions. Ann N Y Acad Sci 1998; 854: 118-127.
91. Beckman KB, Ames BN. Endogenous oxidative damage of mtDNA. Mutat Res 1999; 424: 51-58.
92. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283: 1482-1488.
93. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995; 38: 357-366.
94. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA. Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta 1999; 1410: 171-182.
95. Al-Abdulla NA, Martin LJ. Apoptosis of retrogradely degenerating neurons occurs in association with the accumulation of perikaryal mitochondria and oxidative damage to the nucleus. Am J Pathol 1998; 153: 447-456.
96. Wallace DC. Mitochondrial DNA in aging and disease. Sci Am 1997; 277: 40-47.
97. Aliev G, Shi J, Perry G, Lamb BT, La Manna JC, Friedland RP. Neuronal mitochondrial abnormalities in yeast artificial chromosome (YAC) transgenic mice overexpressing amyloid precursor protein (APP). Society for Neuroscience Abstracts Book 2000; 30.
98. Aliev G, Smith MA, Turmaine M, Neal ML, Zimina TV, Friedland RP, et al. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Exp Mol Pathol 2001; 71: 40-54.
99. Shi J, et al. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. JNM 2002; 43: 1044-1051.
100. Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. In vitro effects of nicotine on mitochondrial respiration and superoxide anion generation. Brain Res 2001; 900: 72-79.
101. De Jong GI, De Vos RA, Steur EN, Luiten PG. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann NY Acad Sci 1997; 826: 56-74.
102. de la Torre JC. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci 1997; 826: 75-91.
103. Friston KJ, Frackowiak RS. Cerebral function in aging and Alzheimer's disease: the role of PET. Electroencephalogr Clin Neurophysiol Suppl 1991; 42: 355-365.
104. Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J Psychiatr Res 1990; 24: 97-109.
105. Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 1999; 122 (Pt 8): 1519-1531.
106. Jagust WJ, Friedland RP, Budinger TF, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 1988; 38: 909-912.
107. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152-1162.
108. Weinbrecht P, Longmuir I, Knopp J, Mills M. Cerebral microcirculatory changes during exposure to hypoxia. Adv Exp Med Biol 1987; 215: 259-263.
109. Mironov V, Hritz MA, LaManna JC, Hudetz AG, Harik SI. Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res 1994; 660: 73-80.
110. Chavez JC, Agani F, Pichiule P, LaManna JC. Expression of hypoxia- inducible factor-1alpha in the brain of rats during chronic hypoxia. J Appl Physiol 2000; 89: 1937-1942.
111. Stewart PA, Isaacs H, LaManna JC, Harik SI. Ultrastructural concomitants of hypoxia-induced angiogenesis. Acta Neuropathol (Berl) 1997; 93: 579-584.
112. LaManna JC, Boehm KD, Mironov V, Hudetz AG, Hritz MA, Yun JK, et al. Increased basic fibroblastic growth factor mRNA in the brains of rats exposed to hypobaric hypoxia. Adv Exp Med Biol 1994; 361: 497-502.
113. Harik N, Harik SI, Kuo NT, Sakai K, Przybylski RJ, LaManna JC. Time-course and reversibility of the hypoxia-induced alterations in cerebral vascularity and cerebral capillary glucose transporter density. Brain Res 1996; 737: 335-338.
114. Bednar MM, Raymond S, McAuliffe T, Lodge PA, Gross CE. The role of neutrophils and platelets in a rabbit model of thromboembolic stroke. Stroke 1991; 22: 44-50.
115. Chen H, Chopp M, Zhang ZG, Garcia JH. The effect of hypothermia on transient middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1992; 12: 621-628.
116. Olah L, Wecker S, Hoehn M. Relation of apparent diffusion coefficient changes and metabolic disturbances after 1 hour of focal cerebral ischemia and at different reperfusion phases in rats. J Cereb Blood Flow Metab 2001; 21: 430-439.
117. Dietrich WD, Busto R, Ginsberg MD. Cerebral endothelial microvilli: formation following global forebrain ischemia. J Neuropathol Exp Neurol 1984; 43: 72-83.
118. Fischer EG, Ames 3rd A. Studies on mechanisms of impairment of cerebral circulation following ischemia: effect of hemodilution and perfusion pressure. Stroke 1972; 3: 538-542.
119. Wade JG, Amtorp O, Sorensen SC. No-flow state following cerebral ischemia. Role of increase in potassium concentration in brain interstitial fluid. Arch Neurol 1975; 32: 381-384.
120. Cada A, de la Torre JC, Gonzalez-Lima F. Chronic cerebrovascular ischemia in aged rats: effects on brain metabolic capacity and behavior. Neurobiol Aging 2000; 21: 225-233.
121. Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994; 78: 927-930.
122. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. Faseb J 1995; 9: 1319-1330.
123. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
124. Crow JP, Ye YZ, Strong M, Kirk M, Barnes S, Beckman JS. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J Neurochem 1997; 69: 1945-1953.
125. Dawson VL, Brahmbhatt HP, Mong JA, Dawson TM. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. Neuropharmacology 1994; 33: 1425-1430.
126. Dawson VL, Dawson TM. Nitric oxide in neuronal degeneration. Proc Soc Exp Biol Med 1996; 211: 33-40.
127. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci U S A 1991; 88: 6368-6371.
128. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997; 100: 2146-2152.
129. Wever RM, Luscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
130. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in argininedepleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770-6774.
131. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-560.
132. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994; 78: 931-936.
133. Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics 1994; 19: 350-357.
134. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-143.
135. Stuehr DJ. Structure-function aspects in the nitric oxide synthases. Annu Rev Pharmacol Toxicol 1997; 37: 339-359.
136. Morris SM, Jr., Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266: E829-E839.
137. Bates TE, Loesch A, Burnstock G, Clark JB. Immunocytochemical evidence for a mitochondrially located nitric oxide synthase in brain and liver. Biochem Biophys Res Commun 1995; 213: 896-900.
138. Bates TE, Loesch A, Burnstock G, Clark JB. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation? Biochem Biophys Res Commun 1996; 218: 40-44.
139. Dawson DA. Nitric oxide and focal cerebral ischemia: multiplicity of actions and diverse outcome. Cerebrovasc Brain Metab Rev 1994; 6: 299-324.
140. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994; 63: 175-195.
141. Wu L, Chang T, Wang R. Inhibition of formation of advanced glycation end products Canada: University of Saskatchewan, 2010.
142. Faraci FM, Brian JE, Jr. Nitric oxide and the cerebral circulation. Stroke 1994; 25: 692-703.
143. Almeida A, Bolanos JP, Medina JM. Nitric oxide mediates glutamate- induced mitochondrial depolarization in rat cortical neurons. Brain Res 1999; 816: 580-586.
144. Beckman JS. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J Dev Physiol 1991; 15: 53-59.
145. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990; 87: 1620-1624.
146. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 1994; 233: 229-240.
147. Cazevieille C, Muller A, Meynier F, Bonne C. Superoxide and nitric oxide cooperation in hypoxia/reoxygenation-induced neuron injury. Free Radic Biol Med 1993; 14: 389-395.
148. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266: 4244-4250.
149. Lafon-Cazal M, Pietri S, Culcasi M, Bockaert J. NMDA-dependent superoxide production and neurotoxicity. Nature 1993; 364: 535-537.
150. Zerangue N, Gao Q, Dower W. Creatine phosphate analog products, compositions and uses thereof. US20100137255 (2010).
151. Faraci FM. Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation. Am J Physiol 1991; 261: H1038-H1042.
152. Fabricius M, Lauritzen M. Examination of the role of nitric oxide for the hypercapnic rise of cerebral blood flow in rats. Am J Physiol 1994; 266: H1457-H1464.
153. Iadecola C. Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia? Proc Natl Acad Sci U S A 1992; 89: 3913-3916.
154. Buisson A, Margaill I, Callebert J, Plotkine M, Boulu RG. Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J Neurochem 1993; 61: 690-696.
155. Buisson A, Plotkine M, Boulu RG. The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. Br J Pharmacol 1992; 106: 766-767.
156. Samadani AF, Dawson TM, Dawson VL. Nitric oxide synthase in model of focal ischemia. Stroke 1997; 28: 1283-1288.
157. Hamada Y, Hayakawa T, Hattori H, Mikawa H. Inhibitor of nitric oxide synthesis reduces hypoxic-ischemic brain damage in the neonatal rat. Pediatr Res 1994; 35: 10-14.
158. Iadecola C, Li J, Ebner TJ, Xu X. Nitric oxide contributes to functional hyperemia in cerebellar cortex. Am J Physiol 1995; 268: R1153-R1162.
159. Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996; 27: 1373-1380.
160. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995; 15: 378-384.
161. Nakashima MN, Yamashita K, Kataoka Y, Yamashita YS, Niwa M. Time course of nitric oxide synthase activity in neuronal, glial, and endothelial cells of rat striatum following focal cerebral ischemia. Cell Mol Neurobiol 1995; 15: 341-349.
162. Wang Q, Pelligrino DA, Baughman VL, Koenig HM, Albrecht RF. The role of neuronal nitric oxide synthase in regulation of cerebral blood flow in normocapnia and hypercapnia in rats. J Cereb Blood Flow Metab 1995; 15: 774-778.
163. Garthwaite J, Beaumont PS. Excitatory amino acid receptors in the parallel fibre pathway in rat cerebellar slices. Neurosci Lett 1989; 107: 151-156.
164. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz MA. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab 1996; 16: 605-611.
165. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-1885.
166. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997; 3: 1089-1095.
167. Thorns V, Hansen L, Masliah E. Nnos expressing neurons in the entorhinal cortex and hippocampus are affected in patients with Alzheimer's disease. Exp Neurol 1998; 150: 14-20.
168. Bogumil R, Knipp M, Fundel SM, Vasak M. Characterization of dimethylargininase from bovine brain: evidence for a zinc binding site. Biochemistry 1998; 37: 4791-4798.
169. Kimoto M, Tsuji H, Ogawa T, Sasaoka K. Detection of NG, NGdimethylarginine dimethylaminohydrolase in the nitric oxidegenerating systems of rats using monoclonal antibody. Arch Biochem Biophys 1993; 300: 657-662.
170. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NGdimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 1995; 117: 237-238.
171. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540.
172. Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature 1993; 364: 584.
173. Gibson GE. Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease. Free Radic Biol Med 2002; 32: 1061-1070.
174. Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum Psychopharmacol 2000; 15: 1-70.
175. Stone J. What initiates the formation of senile plaques? The origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses 2008; 71: 347-359.
176. Obrenovich ME, Smith MA, Siedlak SL, Chen SG, de la Torre JC, Perry G, et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 2006; 10: 43-56.
177. Aliev G, Smith MA, Obrenovich ME, de la Torre JC, Perry G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox Res 2003; 5: 491-504.
178. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11: 721-736.
179. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007; 257: 240-246.
180. Aliev G, Seyidova D, Neal ML, Shi J, Lamb BT, Siedlak SL, et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 2002; 977: 45-64.
181. Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996; 297: 299-306.
182. Suo Z, Wu M, Citron BA, Wong GT, Festoff BW. Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation. J Neurosci 2004; 24: 3444-3452.
183. Brunner F. Interaction of nitric oxide and endothelin-1 in ischemia/ reperfusion injury of rat heart. J Mol Cell Cardiol 1997; 29: 2363-2374.
184. Lerman A, Burnett JC, Jr. Intact and altered endothelium in regulation of vasomotion. Circulation 1992; 86: III12-III19.
185. Lerman A, Hildebrand FL, Jr., Margulies KB, O'Murchu B, Perrella MA, Heublein DM, et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc 1990; 65: 1441-1455.
186. Lerman A, Sandok EK, Hildebrand FL, Jr., Burnett JC, Jr. Inhibition of endothelium-derived relaxing factor enhances endothelinmediated vasoconstriction. Circulation 1992; 85: 1894-1898.
187. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988; 6: S188-S191.
188. Aliev G, Shi J, Perry G, Friedland RP, Lamanna JC. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of donryu rats on a cholesterol-enriched diet. Anat Rec 2000; 260: 16-25.
189. Aliev G, Miah S, Turmaine M, Burnstock G. An ultrastructural and immunocytochemical study of thoracic aortic endothelium in aged Sprague-Dawley rats. J Submicrosc Cytol Pathol 1995; 27: 477-490.
190. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-949.
191. Aliev G, Smith MA, Seyidova D, Neal ML, Shi J, Loizidou M, et al. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J Submicrosc Cytol Pathol 2002; 34: 37-50.
192. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 1998; 85: 502-506.
193. Aliev G, Ralevic V, Burnstock G. Depression of endothelial nitric oxide synthase but increased expression of endothelin-1 immunoreactivity in rat thoracic aortic endothelium associated with long-term, but not short-term, sympathectomy. Circ Res 1996; 79: 317-323.
194. Gokaraju G, Gokaraju R, Golakoti T, Somepalli V. Synergistic anti-inflammatory and antioxidant dietary supplement compositions. US20100098676 (2010).
195. Husband A, James M, Kumar N. 6-substituted isoflavonoid compunds and uses WO2010012037 (2010).